Inclusion Criteria:  The subject is aged 2-17  The subject with one or more of the below at diagnosis  serum c-peptide < 0.6 ng/mL positive glutamic acid decarboxylase (GAD) antibody positive Islet cell antibody positive anti-Insulin antibody positive anti-Islet Antigen-2 (IA-2) antibody The subject was diagnosed with type 1 diabetes ≥ 1 year The subject is treated with multiple daily insulin injection The subject must have available continuous glucose monitoring (CGM) data with a percentage of active CGM time ≥ 70% in the past 4 weeks.  Exclusion Criteria:  Subjects who were treated with insulin pump therapy within 12 weeks prior to trial Any systemic treatment with drugs known to interfere with glucose metabolism within 12 weeks prior to trial Subjects with underlying hematologic disorders that can affect the HbA1c levels Subjects with underlying medical disorders that can affect glucose metabolism Subjects with a neuropsychiatric disorder such as depression or eating disorder Subjects with underlying thyroid disorders and abnormal thyroid function